BioCentury
ARTICLE | Company News

Mela jumps as panel backs MelaFind

November 20, 2010 1:27 AM UTC

Mela Sciences Inc. (NASDAQ:MELA) spiked $2.45 (97%) to $4.98 on Friday after an FDA advisory committee voted 8-7, with one abstention, on Thursday that the benefits of melanoma diagnostic candidate MelaFind outweigh its risks. The General and Plastic Surgery Devices Panel also voted 10-6 that the safety data for MelaFind were adequate and voted 8-2, with two abstentions, that the data showed sufficient efficacy. Mela said FDA has not provided a decision date for the PMA for MelaFind, which is under review to assist in evaluating pigmented skin lesions with characteristics of melanoma prior to biopsy. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article